Exa Corporation (EXA) PT Lowered to $17 at Stifel Following 4Q

Pre-Open Movers 03/17: (GALE) (TIF) (ADBE) Higher; (ESPR) (MDCO) (AMGN) Lower (more...)

Today's Pre-Open Movers

Esperion Therapeutics (Nasdaq: ESPR) 24.5% LOWER; Plunges Following Amgen's (Nasdaq: AMGN)... More

Canaccord Genuity Downgrades Exa Corporation (EXA) to Hold

Canaccord Genuity downgraded Exa Corporation (NASDAQ: EXA) from Buy to Hold with a price target of $15.00 (from $18.00).

Analyst David Hynes commented, "We really wrestled with what to do with our rating on Exa. On the one hand, any shortterm buying pause that is caused by the uncertainties of a prospective border tax or the roll-back of emissions standards should in theory be temporary. If simulation... More

Exa Corporation (EXA) PT Lowered to $16 at Needham & Company Following 'Mixed F4Q17 Results' and 'Policy Uncertainty'

Needham & Company analyst Richard Valera lowered its price target on Exa Corporation (NASDAQ: EXA) to $16.00 (from $18.00) while maintaining a Buy rating, noting management delivered disappointing 2018 guidance due to policy uncertainty, as the company reported mixed fourth quarter results.

Valera comments, "Exa delivered... More

After-Hours Stock Movers 03/16: (AVXS) (ABUS) (VRX) Higher; (CLMS) (EXA) (CAL) Lower (more...)

Today's After-Hours Movers

Cumulus Media (NASDAQ: CMLS) 19.8% LOWER; reported Q4 EPS of ($18.57), which may note compare to the analyst estimate of $0.01. Revenue for the quarter came in at $299.5 million versus the consensus estimate of $308.8 million.

AveXis, Inc. (NASDAQ: AVXS) 12.5% HIGHER; reported topline results from the Phase 1 trial of AVXS-101 in spinal muscular atrophy (SMA) Type 1. The company also reported financial results for the fourth quarter... More

Exa (EXA) Reports Q4 EPS of $0.02

Exa (NASDAQ: EXA) reported Q4 EPS of $0.02. Revenue for the quarter came in at $19.5 million versus the consensus estimate of $20.25 million..

For earnings history and earnings-related data on Exa (EXA) click here.